The prostate cancer market size reached a value of USD 13,049.5 million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 24,930.6 million by ​2035​, exhibiting a growth rate (CAGR) of 6.06% during ​2025-2035​.

By 2025, the prostate cancer field has picked up speed, thanks to precision medicine, fresh therapies, and wider access that are changing how patients get care. Doctors now sit down with patients and map out plans that mix the newest drugs, smart tests, and gentle delivery in hopes of better results. A big reason for this change is the boom in oral hormone meds. Next-generation blockers such as relugolix, darolutamide, and enzalutamide slow the disease with less fuss and a simple pill instead of a shot. Because these medicines can be taken at home, patients find daily dosing far easier to fit into busy lives. Progress with radiopharmaceuticals and theranostics is grabbing attention too. PSMA-targeted treatments like lutetium-177 and the newer terbium-161 hunt down and zap cancer cells with laser-like focus. Early studies show many men experience rapid PSA drops and longer time before the disease spreads. With sharper PSMA PET scans in hand, many doctors now view these options as must-haves for advanced cases.

On the testing side, precision diagnostics are rewriting the market playbook. AI-powered images, plus gene-guided tests such as micro-ultrasound, IsoPSA blood checks, and liquid biopsies, catch problems sooner and with greater accuracy. By pairing these insights with therapy, teams try to fit each man with the treatment that matches his tumor best. New combos and next-gen therapies are opening up more choices for patients. Studies now look at pairing PARP blockers with androgen blockers, along with PROTAC drugs like gridegalutamide and luxdegalutamide, to hit hard-to-treat tumors. These ideas aim straight at resistant disease and give fresh hope to people who have run out of other options.

Request to get a PDF Sample Report: https://www.imarcgroup.com/prostate-cancer-market/requestsample

The report also provides a detailed analysis of the current prostate cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Competitive Landscape

The competitive landscape of the prostate cancer market has been studied in the report with the detailed profiles of the key players operating in the market.

Sanofi-Aventis
Sanofi
Astellas Pharma
Curium Pharma
Curium Pharma

7 Major Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145